Plasma homocysteine levels and the left ventricular systolic function in coronary artery disease patients

Coronary Artery Disease

Volumn 16, Issue 3, 2005, Pages 153-161

  Bokhari, Syed W ^a   Bokhari, Zubaria W ^b   Zell, Jason A ^c   Lee, Don W ^b   Faxon, David P ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Coronary disease; Homocysteine; Left ventricular function

Indexed keywords

HOMOCYSTEINE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTERY OCCLUSION; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DISEASE SEVERITY; FEMALE; HEART FUNCTION; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART VENTRICULOGRAPHY; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SAMPLE SIZE; SCORING SYSTEM; STATISTICAL SIGNIFICANCE;

AGED; CHOLESTEROL, HDL; CONTINENTAL POPULATION GROUPS; CORONARY ARTERIOSCLEROSIS; DIABETES MELLITUS, TYPE 1; FEMALE; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; MALE; MULTIVARIATE ANALYSIS; SEVERITY OF ILLNESS INDEX; STROKE VOLUME; SYSTOLE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 17844365299     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-200505000-00004     Document Type: Article

References (93)

1. Reigel B, du Vigneaud V. The isolation of homocysteine and its conversion to thiolactone. J Biol Chem 1935; 112:149-154.
2. Mayer EL, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol 1996; 27:517-527.
3. Ogino S, Wilson RB. Genotype and haplotype distributions of MTHFR677C>T and 1298A>C single nucleotide polymorphisms: a meta-analysis. J Hum Genet 2003; 48:1-7.
4. Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG. MTHFR 677C→T polymorphism and risk of coronary heart disease:a meta-analysis. JAMA 2002; 288:2023-2031.
5. Kelly RJ, Rosand J, Kistler JP, Shih VE, Silveira S, Plomaritoglou A. Homocysteine, MTHFR 677C→T polymorphism, and risk of ischemic stroke: results of a meta-analysis. Neurology 2002; 59:529-536
6. Andreassi MG, Botto N, Cocci F, Battaglia D, Antoniloi E, Masetti S, et al. Methylenetetrahydrofolate reductase gene C677T polymorphism, homocysteine, vitamin B12, and DNA damage in coronary artery disease. Hum Genet 2003; 112:171-177.
7. Malinow MR, Duell PB, Hess DL, Anderson PH, Kruger WD, Phillipson BE, et al. Reduction of plasma homocysteine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. N Engl J Med 1998; 338:1009-1015.
8. Chasan-Taber L, Selhub J, Rosenberg IH, Malinow MR, Terry P, Tishler PV, et al. A prospective study of folate and vitamin B6 and risk of myocardial infarction in US physicians. J Am Coll Nutr 1996; 15:136-143.
9. McCully KS. Homocysteine and vascular disease. Nat Med 1996; 2:386-389.
10. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991; 324:1149-1155.
11. Ueland PM, Refsum H. Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease, and drug therapy. J Lab Clin Med 1989; 114:473-501.
12. Verhoef P, Kok FJ, Kruyssen DA, Schouten EG, Grobbee DE, Ueland PM, et al. Plasma total homocysteine, B vitamins, and risk of coronary atherosclerosis. Arterioscler Thromb Vasc Biol 1997; 17:989-995.
13. Montalescot G, Ankri A, Chadefaux-Vekemans B, Blacher J, Phillipe F, Drobinski, et al. Plasma homocysteine and the extent of atherosclerosis in patients with coronary artery disease. Int J Cardiol 1997; 60:295-300.
14. Malinow MR, Nieto FJ, Szklo M, Chambless LE, Bond G. Carotid artery intimal-medial wall thickening and plasma homocysteine in asymptomatic adults. The Atherosclerosis Risk in Communities Study. Circulation 1993; 87:1107-1113.
15. Aronow WS, Ahn C, Schoenfeld MR. Association between plasma homocysteine and extracranial carotid arterial disease in older persons. Am J Cardiol 1997; 79:1432-1433.
16. Selhub J, Jacques PF, Bostom AG, D'Agostino RB, Wilsn PW, Belanger AJ, et al. Association between plasma homocysteine concentrations and extracranial carotid artery stenosis. N Engl J Med 1995; 332:286-291.
17. Berg M, Stehouwer CD, Bierdrager E, Rauwerda JA. Plasma homocysteine and severity of atherosclerosis in young patients with lower-limb atherosclerotic disease. Arterioscler Thromb Vasc Biol 1996; 16:165-171.
18. Bostom AG, Selhub J. Homocysteine and arteriosclerosis. Circulation 1999; 99:2361-2363.
19. Eikelboom JW, Lonn E, Genest J Jr, Hankey G, Yusuf S. Homocysteine and cardiovascular disease. Ann Intern Med 1999; 131:363-375.
20. Refsum H, Ueland PM, Nygard O, Vollset SE. Homocysteine and cardiovascualr disease. Annu Rev Med 1998; 49:31-62.
21. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary heart disease. N Engl J Med 1997; 337:230-236.
22. Kang SS, Wong PW, Cook HY, Norusis M, Messer JV. Protein-bound homocysteine: a possible risk factor for coronary artery disease. J Clin Invest 1986; 77:1482-1486.
23. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D, et al. A prospective study of plasma homocysteine and risk of myocardial infarctions in US physicians. JAMA 1992; 268:877-881.
24. Murphy-Chutorian D, Alderman EL. The case that hyperhomocysteinemia is a risk factor for coronary artery disease. Am J Cardiol 1994; 73:705-707.
25. Arnesen E, Refsum H, Bonna KH, Ueland PM, Forde OH, Nordrehaug JE. Serum total homocysteine and coronary artery disease. Int J Epidemiol 1995; 24:704-709.
26. Acevedo M, Pearce GL, Kottke-Marchant K, Sprecher DL. Elevated fibrinogen and homocysteine levels enhance the risk of mortality in patients from a high-risk preventive cardiology clinic. Arterioscler Thromb Vasc Biol 2002; 22:1042-1045.
27. Anderson JL, Muhlestein JB, Horne BD, Carlquist JF, Tami L, Troy BA, et al. Plasma homocysteine predicts mortality independently of traditional risk factors and C-reactive protein in patients with angiographically defined coronary artery disease. Circulation 2000; 102:1227-1232.
28. Stehouwer CD, Gall MA, Hougaard P, Jakobs C, Parving HH. Plasma homocysteine concentration predicts mortality in non-insulin dependent diabetic patients with and without albuminuria. Kidney Int 1999; 55:308-314.
29. Bostom AG, Silbershatz H, Rosenberg IH, Selhub J, D'Agostino RB, Wolf PA, et al. Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women. Arch Int Med 1999; 159:1077-1080.
30. Pajunen P, Syvanne M, Niemaen MS, Kareinen A, Viitanen L, Lehto S, et al. Serum homocysteine, creatinine, and glucose as predictors of the severity and extent of coronary artery disease in asymptomatic members of high-risk families. Eur J Clin Invest 2002; 32:472-478.
31. Tsai WC, Li YH, Tsai LM, Chao TH, Lin LJ, Chen TY, et al. Correlation of homocysteine levels with the extent of coronary atherosclerosis in patients with low cardiovascular risk profiles. Am J Cardiol 2000; 85:49-52.
32. Chao CL, Tsai HH, Lee CM, Hsu SM, Kao JT, Chien KL, et al. The graded effect of hyperhomocysteinemia on the severity and extent of coronary atherosclerosis. Atherosclerosis 1999; 147:379-386.
33. Snyder G, Pin R, Roffi M, Flammer Y, Hess OM. Association of plasma homocysteine with the number of major coronary arteries severely narrowed. Am J Cardiol 2001; 88:1027-1030.
34. Tokgozoglu SL, Alikasfoglu M, Unsal, Atalar E, Aytemir K, Ozer N, et al. Methylene tetrahydrofolate reductase genotype and the risk and extent of coronary artery disease in a population with low plasma folate. Heart 1999; 81:518-522.
35. Liu H, Gao R, Hui R, Chen J, Zhang C, Wu Y. The association between plasma homocysteine and the number of coronary artery with stenosis. Zhongua Nei Ke Za Zhi 1999; 38:821-823.
36. Bozkurt A, Toyaksi H, Acarturk E, Tuli A, Cayli M. The effects of hyperhomocysteinemia on the presence, extent, and severity of coronary artery disease. Jpn Heart J 2003; 44:357-368.
37. Brilakis ES, McConnell JP, Ballman KV, Klee GG, Berger PB. Lack of association between plasma homocysteine and angiographic coronary artery disease in the era of fortification of cereal grain flour with folic acid. Atherosclerosis 2002; 165:375-381.
38. Herzlich BC, Lichstein E, Schulhoff N, Weinstock M, Pagala M, Ravindran K, et al. Relationship among homocysteine, vitamin B-12 and cardiac disease in the elderly: association between vitamin B-12 deficiency and decreased left ventricular ejection fraction. J Nutr 1996; 126:1249S-1253S.
39. Nikfardjam M, Graf S, Hornykewycz S, Zorn G, Huber-Beckmann R, Wojta J, et al. Homocysteine plasma levels in young patients with coronary artery disease. Relation to history of myocardial infarction and anatomical extent of disease. Thromb Res 2001; 103S:535-539.
40. Wang XL, Duarte N, Cai H, Adachi T, Sim AS, Cranney G, et al. Relationship between total plasma homocysteine, polymorphisms of homocysteine metabolism related enzymes, risk factors and coronary artery disease in the Australian hospital-based population. Atherosclerosis 1999; 146:133-140.
41. Abdel-Mouttaleb I, Danchin N, Aimone-Gastin I, Namour F, Angioi M, Gelot MA, et al. Homocysteine, vitamins B6, B12, folate, and risk of coronary artery disease in patients undergoing diagnostic coronary angiography. Amino Acids 2000; 18:139-146.
42. Fiskerstrand T, Refsum H, Kvalliem G, Ueland PM. Homocysteine and their thiols in plasma and urine: automated determination and sample stability. Clin Chem 1993; 39:263-271.
43. Refsum H, Ueland PM, Svardal AM. Fully automated fluorescence assay for determining total homocysteine in plasma. Clin Chem 1989; 35:1921-1927.
44. Senaratne MP, MacDonald K, de Silva D. Possible ethnic differences in plasma homocysteine levels associated with coronary artery disease between south Asian and east Asian immigrants. Clin Cardiol 2001; 24:730-734.
45. Morris MS, Bostom AG, Jacques PF, Selhub J, Rosenberg IH. Hyperhomocysteinemia and hypercholesterolemia associated with hypothyroidism in the third US National Health and Nutrition Examination Survey. Atherosclerosis 2001; 155:195-200.
46. Bostom AG, Gohh RY, Liaugaudas G, Beaulieu AJ, Han H, Jacques PF, et al. Prevalence of mild fasting hyperhomocysteinemia in renal transplant versus coronary artery disease patients after fortification of cereal grain flour with folic acid. Atherosclerosis 1999; 145:221-224.
47. Gensini GG. Coronary arteriography. In: The pathological anatomy of the coronary arteries of man. New York: Futura; 1975, pp. 260-274.
48. Chen P, Poddar R, Tipa EV, Dibello PM, Moravec CD, Robinson K, et al. Homocysteine metabolism in cardiovascular cells and tissue. Adv Enzyme Reg 1999; 39:93-109.
49. Loscalzo J. The oxidant stress of hyperhomocysteinemia. J Clin Invest 1996; 98:5-7.
50. Miller A, Mujamdar V, Palmer L, Bower JD, Tyagi SC. Reversal of endocardial endothelial dysfunction by folic acid in homocysteinemic hypertensive rats. Am J Hypertens 2002; 15:157-163.
51. Blacher J, Demuth K, Guerin AP, Vadez C, Moatti N, Safar ME, London GM. Association between plasma homocysteine concentrations and cardiac hypertrophy in end-stage renal disease. J Nephrol 1999; 12: 248-255.
52. Whincup PH, Refsum H, Perry IJ, Morris R, Walker M, Lenon L, et al. Serum total homocysteine and coronary heart disease: prospective study in middle aged men. Heart 1999; 82:448-454.
53. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998; 338:1042-1050.
54. Al Obaidi MK, Stubbs PJ, Collinson P, Conroy R, Graham I, Noble MI. Elevated homocysteine levels are associated with increased ischemic myocardial injury in acute coronary syndromes. J Am Coll Cardiol 2000; 36:1217-1222.
55. Vasan SR, Beiser A, D'Agostino R, Levy D, Selhub J, Jacques PF, et al. Plasma homocysteine and risk for congestive heart failure in adults without prior myocardial infarction. JAMA 2003; 289:1251-1257.
56. Cooke GE, Eaton GM, Whitby G, Kennedy RA, Binkley PF, Moeschberger ML, Leier CV, et al. Plasma atherogenic markers in congestive heart failure and posttransplant (heart) patients. J Am Coll Cardiol 2000; 36:509-516.
57. Ventura P, Panini R, Verlato C, Scarpetta G, Salvioli G. Hyperhomocysteinemia and related factors in 600 hospitalized elderly subjects. Metabolism 2001; 50:1466-1471.
58. Lentz SR. Homocysteine and vascular dysfunction. Life Sci 1997; 61:1205-1215.
59. Chilian WM. Coronary microcirculation in health and disease. Circulation 1997; 95:522-528.
60. Symons JD, Mullick AE, Ensunsa JL, Ma AA, Rutledge JC. Hyperhomocysteinemia evoked by folate depletion. Arterioscler Thromb Vasc Biol 2002; 22:772-780.
61. Jourdeheuil-Rahmani D, Rolland PH. Homocysteine induces synthesis of a serine elastase in arterial smooth muscle cells from multi-organ donors. Cardiovasc Res 1997; 34:597-602.
62. Tyagi SC. Homocysteine and heart disease: pathophysiology of extracellular matrix. Clin Exp Hypertens 1999; 21:181-198.
63. Tyagi SC, Smiley LM, Mujumdar VS. Homocysteine impairs endocardial endothelial function. Can J Physiol Pharmacol 1999; 77:950-957.
64. McCully KS. Vascular pathology of homocysteinemia:implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969; 56:111-128.
65. Wilcken DE, Wilcken B. The pathogenesis of coronary artery disease: a possible role of methionine metabolism. J Clin Invest 1976; 57:1079-1082.
66. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA 1995; 274:1049-1057.
67. Bautista LE, Arenas IA, Anderson P, Martinez LX. Total plasma homocysteine level and risk of cardiovascular disease; A meta-analysis of prospective cohort studies. J Clin Epidemiol 2002; 55:882-887.
68. Wilcken DE, Wilcken B. The natural history of vascular disease in homocysteinuria and the effects of treatment. J Inherit Metab Dis 1997; 20:295-300.
69. Schnyder G, Roffi M, Pin R, Flammer Y, Lange H, Eberli FR, et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 2001; 345:1593-1600.
70. Anderson JL, Muhlestein JB, Horne BD, Carlquist JF, Tami L, Troy BA, et al. Plasma Homocysteine predicts mortality independently of traditional risk factors and C-reactive protein in patients with angiographically defined coronary artery disease. Circulation 2000; 102:1227-1232.
71. Willems FF, Aengevaeren WR, Boers GH, Blom HJ, Verheugt FW. Coronary endothelial function in hyperhomocysteinemia: improvement after treatment with folic acid and cobalamin in patients with coronary artery disease. J Am Coll Cardiol 2002; 40:766-772.
72. Schnyder G, Flammer Y, Roffi M, Pin R, Hess OM. Plasma homocysteine levels and late outcome after coronary angioplasty. J Am Coll Cardiol 2002; 40:1769-1776.
73. Harker LA, Ross R, Slichter SJ, Scott CR. Homocysteine-induced arteriosclerosis: the role of endothelial cell injury and platelet response in its genesis. J Clin Invest 1976; 58:731-741.
74. Lentz SR, Sadler JE. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest 1991; 88:1906-1914.
75. Rantoff OD. Activation of Hageman factor by I-homocysteine. Science 1968; 162:1007-1009.
76. Rodgers GM, Kane WH. Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator. J Clin Invest 1986; 77:1909-1916.
77. Rodgers GM, Conn MT. Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood 1990; 75:895-901.
78. Nishinaga M, Ozawa T, Shimada K. Homocysteine, a thromboogenic agent, suppresses anticoagulant heparin sulfate expression in cultured porcine aortic endothelial cells. J Clin Invest 1993; 92:1381-1386.
79. Stamler JS, Osborne JA, Jaraki O, Rabbani LE, Mullins M, Single D, et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993; 91:308-318.
80. Tawakol A, Omland T, Gerhard M, Wu JT, Creager MA. Hyperhomocysteinemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation 1997; 95:1119-1121.
81. Majors A, Ehrhart LA, Pezacka EH. Homocysteine as a risk factor for vascular disease. Enhanced collagen production and accumulation by smooth muscle cells. Arterioscler Thromb Vasc Biol 1997; 17:2074-2081.
82. Kanani PM, Sinkey CA, Browning RL, Allaman M, Knapp HR, Haynes WG. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocysteinemia in humans. Circulation 1999; 100:1161-1168.
83. Poddar R, Sivasubramanian N, DiBello PM, Robinson K, Jacobsen DW. Homocysteine induces expression and secretion of monocyte chemoattractant protein-1 and interleukin-8 in human aortic endothelial cells: implications for vascular disease. Circulation 2001; 103:2717-2723.
84. Nappo F, De Rosa N, Marfella R, De Lucia D, Ingrosso D, Perna AF, et al. Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins. JAMA 1999; 281:2113-2118.
85. Blom HJ, Engelen DP, Boers GH, Stadhouders AM, Sengers RC, de Abreu R, et al. Lipid peroxidation in homocysteinemia. J Inherit Metab Dis 1992; 15:419-422.
86. Heinecke JW, Kawamura M, Suzuki L, Chait A. Oxidation of low density lipoprotein by thiols: superoxide-dependent and -independent mechanisms. J Lipid Res 1993; 34:2051-2061.
87. Mangoni AA, Jackson SHD. Homocysteine and cardiovascular disease: current evidence and future prospects. Am J Med 2002; 112:556-565.
88. Giles WH, Croft JB, Greenland KJ, Ford ES, Kittner SJ. Association between total homocysteine and the likelihood for history of acute myocardial infarction by race and ethnicity: results from the Third National Health and Nutrition Examination Survey. Am Heart J 2000; 139:446-453.
89. Os I, Os A, Sandset PM, Bolling S, Seljeflot I, Djurovic S et al. Hormone replacement therapy does not affect plasma homocysteine in postmenopausal women with coronary artery disease. Free tissue factor pathway inhibitor antigen, a circulating anticoagulant, is related to plasma homocysteine. Cardiology 2002; 98:6-12.
90. Hofmann MA, Kohl B, Zumbach MS, Borcea V, Bierhaus A, Henkels M, et al. Hyperhomocysteinemia nad endothelial dysfunction in IDDM. Diabetes Care 1997; 20:1880-1886.
91. Giles WH, Croft JB, Greenland KJ, Ford ES, Kittner SJ. Total homocysteine concentration and the likelihood of nonfatal stroke. Results from the Third National Health and Nutrition Examination Survey, 1988-1994. Stroke 1998; 29:2473-2477.
92. Araki A, Sako Y, Ito H. Plasma hoocysteine concentrations in Japanese patients with non-insulin-dependent diabetes mellitus: effect of parenteral methylcobalamin treatment. Atherosclerosis 1993; 103:149-157.
93. Chico A, Perez A, Cordoba A, Arcclus R, Carreras G, de Leiva A, et al. Plasma homocysteine is related to albumin excretion rate in patients with diabetes mellitus:a new link between diabetic nephropathy and cardiovascular disease? Diabetologica 1998; 41:684-693.